Real-world comparison of health care utilization between duloxetine and pregabalin initiators with fibromyalgia

Journal of Pain Research

Volumn 7, Issue , 2014, Pages 37-46

  Peng, X ^a   Sun, P ^b   Novick, D ^a   Andrews, J ^a   Sun, S ^b  

^a ELI LILLY AND COMPANY   (United States)

^b Kailo Research Group   (United States)

Author keywords

Duloxetine; Fibromyalgia; Health care utilization; Pregabalin; Propensity score methods

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DULOXETINE; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; PREGABALIN; SEROTONIN 3 ANTAGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DRUG UTILIZATION; FEMALE; FIBROMYALGIA; HEADACHE; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITAL CARE; HOSPITAL PATIENT; HUMAN; HYPERTENSION; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIGRAINE; NEUROPATHIC PAIN; OSTEOARTHRITIS; OUTPATIENT; OUTPATIENT CARE; PERIPHERAL NEUROPATHY; PILL; PREVALENCE; PROPENSITY SCORE; RETROSPECTIVE STUDY; YOUNG ADULT;

EID: 84892156407     PISSN: 11787090     EISSN: None     Source Type: Journal    
DOI: 10.2147/JPR.S51636     Document Type: Article

References (87)

1. Sun P, Peng X, Sun S, et al. Direct medical costs and medication compliance among fibromyalgia patients: duloxetine initiators vs pregabalin initiators. Pain Pract. Epub March 14, 2013.
2. Sun P, Zhao Y, Zhao Z, Watson P. Medication dosing patterns associated with duloxetine and pregabalin among patients with fibromyalgia. Curr Med Res Opin. 2011;27(9):1793-1801.
3. Zhao Y, Sun P, Bernauer M. Comparing common reasons for inpatient and outpatient visits between commercially-insured duloxetine or pregabalin initiators with fibromyalgia. J Pain Res. 2015:443-451.
4. Zhao Y, Sun P, Watson P, Mitchell B, Swindle R. Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia. Pain Pract. 2011;11(3):204-216.
5. Marcus DA, Richards KL, Chambers JF, Bhowmick A. Fibromyalgia family and relationship impact exploratory survey. Musculoskeletal Care. 2013;11(3):125-134.
6. Fors EA, Landmark T, Bakke Ø. Contextual and time dependent pain in fibromyalgia: an explorative study. BMC Res Notes. 2012;5:644.
7. Castro-Sánchez AM, Matarán-Peñarrocha GA, López-Rodríguez MM, Lara-Palomo IC, Arendt-Nielsen L, Fernández-de-las-Peñas C. Gender differences in pain severity, disability, depression, and widespread pressure pain sensitivity in patients with fibromyalgia syndrome without comorbid conditions. Pain Med. 2012;13(12):1639-1647.
8. Auquier L, Bontoux D, Löo H, et al. La fibromyalgie. [Fibromyalgia]. Rev Med Interne. 2008;29(2):161-168. French.
9. Wolfe F, Hawley DJ, Goldenberg DL, Russell IJ, Buskila D, Neumann L. The assessment of functional impairment in fibromyalgia (FM): Rasch analyses of 5 functional scales and the development of the FM Health Assessment Questionnaire. J Rheumatol. 2000;27(8):1989-1999.
10. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33(2):160-172.
11. Al-Allaf AW. Work disability and health system utilization in patients with fibromyalgia syndrome. J Clin Rheumatol. 2007;13(4):199-201.
12. Robinson RL, Jones ML. In search of pharmacoeconomic evaluations for fibromyalgia treatments: a review. Expert Opin Pharmacother. 2006;7(8):1027-1039.
13. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007;8:27.
14. Shaver JL, Wilbur J, Robinson FP, Wang E, Buntin MS. Women's health issues with fibromyalgia syndrome. J Womens Health (Larchmt). 2006;15(9):1035-1045.
15. Rutledge DN, Jones K, Jones CJ. Predicting high physical function in people with fibromyalgia. J Nurs Scholarsh. 2007;39(4):319-324.
16. Berger A, Dukes E, Martin S, Edelsberg J, Oster G. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract. 2007;61(9):1498-1508.
17. Panton LB, Kingsley JD, Toole T, et al. A comparison of physical functional performance and strength in women with fibromyalgia, age- and weight-matched controls, and older women who are healthy. Phys Ther. 2006;86(11):1479-1488.
18. Verbunt JA, Pernot DH, Smeets RJ. Disability and quality of life in patients with fibromyalgia. Health Qual Life Outcomes. 2008;6:8.
19. Kurtze N, Gundersen KT, Svebak S. Quality of life, functional disability and lifestyle among subgroups of fibromyalgia patients: the significance of anxiety and depression. Br J Med Psychol. 1999;72(Pt 4):471-484.
20. Wolfe F, Petri M, Alarcón GS, et al. Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity. J Rheumatol. 2009;36(1):82-88.
21. Better Medicine. Prevalence and incidence of fibromyalgia. Available from: http://www.localhealth.com/article/fibromyalgia. Accessed May 5, 2009.
22. National Fibromyalgia Association. Prevalence of fibromyalgia. Available from: http://fmaware.org/PageServera6cc.html?pagename=fibromyalgia_affected. Accessed May 5, 2009.
23. Branco JC, Bannwarth B, Failde I, et al. Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum. 2010;39(6): 448-453.
24. Bannwarth B, Blotman F, Roué-Le Lay K, Caubère JP, André E, Taïeb C. Fibromyalgia syndrome in the general population of France: a prevalence study. Joint Bone Spine. 2009;76(2):184-187.
25. Mas AJ, Carmona L, Valverde M, Ribas B; EPISER Study Group. Prevalence and impact of fibromyalgia on function and quality of life in individuals from the general population: results from a nationwide study in Spain. Clin Exp Rheumatol. 2008;26(4):519-526.
26. Toda K. The prevalence of fibromyalgia in Japanese workers. Scand J Rheumatol. 2007;36(2):140-144.
27. Weir PT, Harlan GA, Nkoy FL, et al. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes. J Clin Rheumatol. 2006;12(3):124-128.
28. Topbas M, Cakirbay H, Gulec H, Akgol E, Ak I, Can G. The prevalence of fibromyalgia in women aged 20-64 in Turkey. Scand J Rheumatol. 2005;34(2):140-144.
29. Sardini S, Ghirardini M, Betelemme L, Arpino C, Fatti F, Zanini F. Studio epidemiologico sulla fibromialgia primaria in eta pediatrica. [Epidemiological study of a primary fibromyalgia in pediatric age.] Minerva Pediatr. 1996;48(12):543-550. Italian.
30. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38(1):19-28.
31. Kim SK, Kim SH, Lee CK, et al. Effect of fibromyalgia syndrome on the health-related quality of life and economic burden in Korea. Rheumatology (Oxford). 2013;52(2):311-320.
32. Robinson RL, Kroenke K, Mease P, et al. Burden of illness and treatment patterns for patients with fibromyalgia. Pain Med. 2012;13(10): 1366-1376.
33. Perrot S, Schaefer C, Knight T, Hufstader M, Chandran AB, Zlateva G. Societal and individual burden of illness among fibromyalgia patients in France: association between disease severity and OMERACT core domains. BMC Musculoskelet Disord. 2012;13:22.
34. Chandran A, Schaefer C, Ryan K, Baik R, McNett M, Zlateva G. The comparative economic burden of mild, moderate, and severe fibromyalgia: results from a retrospective chart review and cross-sectional survey of working-age US adults. J Manag Care Pharm. 2012;18(6): 415-426.
35. Schaefer C, Chandran A, Hufstader M, et al. The comparative burden of mild, moderate and severe fibromyalgia: results from a cross-sectional survey in the United States. Health Qual Life Outcomes. 2011;9:71.
36. Spaeth M. Epidemiology, costs, and the economic burden of fibromyalgia. Arthritis Res Ther. 2009;11(3):117.
37. Kleinman N, Harnett J, Melkonian A, et al. Burden of fibromyalgia and comparisons with osteoarthritis in the workforce. J Occup Environ Med. 2009;51(12):1384-1393.
38. Annemans L, Le Lay K, Taïeb C. Societal and patient burden of fibromyalgia syndrome. Pharmacoeconomics. 2009;27(7):547-559.
39. Doron Y, Peleg R, Peleg A, Neumann L, Buskila D. The clinical and economic burden of fibromyalgia compared with diabetes mellitus and hypertension among Bedouin women in the Negev. Fam Pract. 2004;21(4):415-419.
40. Carville SF, Arendt-Nielsen S, Bliddal H, et al; EULAR. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008;67(4):536-541.
41. Guymer EK, Littlejohn GO. Fibromyalgia. Diagnosis and management. Australas Chiropr Osteopathy. 2002;10(2):81-84.
42. Sumpton JE, Moulin DE. Fibromyalgia: presentation and management with a focus on pharmacological treatment. Pain Res Manag. 2008;13(6):477-483.
43. Buckhardt CS, Goldenberg D, Crofford L, et al. Guideline for the Management of Fibromyalgia Syndrome. Pain in Adults and Children. APS Clinical Practice Guideline Series No 4. Glenview, IL: American Pain Society; 2005.
44. Häuser W, Thieme K, Turk DC. Guidelines on the management of fibromyalgia syndrome - a systematic review. Eur J Pain. 2010;14(1):5-10.
45. Forseth K KØ, Gran JT. Management of fibromyalgia: what are the best treatment choices? Drugs. 2002;62(4):577-592.
46. Brosseau L, Wells GA, Tugwell P, et al; Ottawa Panel Members. Ottawa Panel evidence-based clinical practice guidelines for aerobic fitness exercises in the management of fibromyalgia: part 1. Phys Ther. 2008;88(7):857-871.
47. Brosseau L, Wells GA, Tugwell P, et al; Ottawa Panel Members. Ottawa Panel evidence-based clinical practice guidelines for strengthening exercises in the management of fibromyalgia: part 2. Phys Ther. 2008;88(7):873-886.
48. Crofford LJ. Pain management in fibromyalgia. Curr Opin Rheumatol. 2008;20(3):246-250.
49. Crofford LJ, Rowbotham MC, Mease PJ, et al; Pregabalin 1008-1105 Study Group. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(4):1264-1273.
50. Calandre EP, Morillas-Arques P, Rodriguez-Lopez CM, Rico-Villademoros F, Hidalgo J. Pregabalin augmentation of quetiapine therapy in the treatment of fibromyalgia: an open-label, prospective trial. Pharmacopsychiatry. 2007;40(2):68-71.
51. Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008;136(3):419-431.
52. Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008;35(3):502-514.
53. García-Campayo J, Serrano-Blanco A, Rodero B, et al. Effectiveness of the psychological and pharmacological treatment of catastrophization in patients with fibromyalgia: a randomized controlled trial. Trials. 2009;10:24.
54. Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 2008;136(3):432-444.
55. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119(1-3):5-15.
56. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50(9):2974-2984.
57. Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther. 2008;30(11):1988-2004.
58. Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol. 2005;32(10):1975-1985.
59. Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol. 2004;19 Suppl 1:S27-S35.
60. Reed C, Birnbaum HG, Ivanova JI, et al. Real-world role of tricyclic antidepressants in the treatment of fibromyalgia. Pain Pract. 2012;12(7): 533-540.
61. Gore M, Tai KS, Chandran A, Zlateva G, Leslie D. Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with fibromyalgia newly prescribed pregabalin or tricyclic antidepressants. J Med Econ. 2012;15(1):32-44.
62. Gore M, Tai KS, Chandran A, Zlateva G, Leslie D. Clinical comorbidities, treatment patterns, and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual care. J Med Econ. 2012;15(1):19-31.
63. Burke JP, Sanchez RJ, Joshi AV, Cappelleri JC, Kulakodlu M, Halpern R. Health care costs in patients with fibromyalgia on pregabalin vs duloxetine. Pain Pract. 2012;12(1):14-22.
64. Harnett J, Margolis J, Cao Z, et al. Real-world evaluation of health-care resource utilization and costs in employees with fibromyalgia treated with pregabalin or duloxetine. Pain Pract. 2011;11(3):217-229.
65. Rodriguez-Revenga L, Madrigal I, Blanch-Rubió J, et al. Screening for the presence of FMR1 premutation alleles in women with fibromyalgia. Gene. 2013;512(2):305-308.
66. Berger A, Sadosky A, Dukes EM, Edelsberg J, Zlateva G, Oster G. Patterns of healthcare utilization and cost in patients with newly diagnosed fibromyalgia. Am J Manag Care. 2010;16(Suppl 5):S126-S137.
67. Berger A, Sadosky A, Dukes E, Martin S, Edelsberg J, Oster G. Characteristics and patterns of healthcare utilization of patients with fibromyalgia in general practitioner settings in Germany. Curr Med Res Opin. 2008;24(9):2489-2499.
68. Horndasch S. Hohe Inanspruchnahme des Gesundheitswesens durch Fibromyalgiepatienten. [High utilization of health care services by fibromyalgia patients.] Schmerz. 2009;23(1):70-71. German.
69. Palacio A, Uribe CL, Li H, et al. Financial and clinical characteristics of fibromyalgia: a case-control comparison. Am J Manag Care. 2010;16(Suppl 5):S118-S125.
70. Sanchez RJ, Uribe C, Li H, et al. Longitudinal evaluation of health care utilization and costs during the first three years after a new diagnosis of fibromyalgia. Curr Med Res Opin. 2011;27(3):663-671.
71. White KP, Nielson WR, Harth M, Ostbye T, Speechley M. Does the label "fibromyalgia" alter health status, function, and health service utilization? A prospective, within-group comparison in a community cohort of adults with chronic widespread pain. Arthritis Rheum. 2002;47(3): 260-265.
72. Wolfe F, Anderson J, Harkness D, et al. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum. 1997;40(9):1560-1570.
73. Hudson JI, Goldenberg DL, Pope HG Jr, Keck PE Jr, Schlesinger L. Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med. 1992;92(4):363-367.
74. Raphael KG, Janal MN, Nayak S. Comorbidity of fibromyalgia and posttraumatic stress disorder symptoms in a community sample of women. Pain Med. 2004;5(1):33-41.
75. Bradley LA. Psychiatric comorbidity in fibromyalgia. Curr Pain Headache Rep. 2005;9(2):79-86.
76. Chamizo-Carmona E. Existe asociación entre la fibromialgia, el aumento de la comorbilidad por enfermedad neoplásica, cardiovascular e infecciones, y el de la mortalidad? [Is there an association between fibromyalgia and an increase in comorbidity: neoplastic and cardiovascular diseases, infections and mortality?] Reumatol Clin. 2005;1(4):200-210. Spanish.
77. Buskila D, Cohen H. Comorbidity of fibromyalgia and psychiatric disorders. Curr Pain Headache Rep. 2007;11(5):333-338.
78. Gil Yubero J, Llensa Cubarsí I, Mas Marquès M, Buñuel Alvarez JC. Comorbilidad registrada en los pacientes diagnosticados de fibromialgia en un centro de atención primaria. [Comorbidity recorded in patients diagnosed with fibromyalgia at a primary care centre.] Aten Primaria. 2007;39(4):217. Spanish.
79. White LA, Birnbaum HG, Kaltenboeck A, Tang J, Mallett D, Robinson RL. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med. 2008;50(1):13-24.
80. de Tommaso M, Sardaro M, Serpino C, et al. Fibromyalgia comorbidity in primary headaches. Cephalalgia. 2009;29(4):453-464.
81. González E, Elorza J, Failde I. Fibromyalgia and psychiatric comorbidity: their effect on the quality of life patients. Actas Esp Psiquiatr. 2010;38(5):295-300. Spanish.
82. Shillam CR, Dupree Jones K, Miller L. Fibromyalgia symptoms, physical function, and comorbidity in middle-aged and older adults. Nurs Res. 2011;60(5):309-317.
83. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects Biometrika. 1983;70(1): 41-55.
84. Guo SY, Fraser MW. Propensity Score Matching and Related Models. Propensity Score Analysis: Statistical Methods and Applications. Los Angeles: SEGA; 2010:145-149.
85. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265-2281.
86. Dehejia RH, Wahba S. Propensity score-matching methods for nonexperimental causal studies. Rev Econ Stat. 2002;84(1): 151-161.
87. Kleinman NL, Sanchez RJ, Lynch WD, Cappelleri JC, Beren IA, Joshi AV. Health outcomes and costs among employees with fibromyalgia treated with pregabalin vs standard of care. Pain Pract. 2011;11(6): 540-551.